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ABSTRACT: An optimized peptide substrate was used to measure
protein kinase B (PKB) activity in single cells. The peptide substrate
was introduced into single cells, and capillary electrophoresis was
used to separate and quantify nonphosphorylated and phosphory-
lated peptide. The system was validated in three model pancreatic
cancer cell lines before being applied to primary cells from human
pancreatic adenocarcinomas propagated in nude mice. As measured
by phosphorylation of peptide substrate, each tumor cell line
exhibited statistically different median levels of PKB activity (65%,
21%, and 4% phosphorylation in PANC-1 (human pancreatic
carcinoma), CFPAC-1 (human metastatic ductal pancreatic adenocarcinoma), and HPAF-II cells (human pancreatic
adenocarcinoma), respectively) with CFPAC-1 cells demonstrating two populations of cells or bimodal behavior in PKB
activation levels. The primary cells exhibited highly variable PKB activity at the single cell level, with some cells displaying little to
no activity and others possessing very high levels of activity. This system also enabled simultaneous characterization of peptidase
action in single cells by measuring the amount of cleaved peptide substrate in each cell. The tumor cell lines displayed
degradation rates statistically similar to one another (0.02, 0.06, and 0.1 zmol pg−1 s−1, for PANC-1, CFPAC-1, and HPAF-II
cells, respectively) while the degradation rate in primary cells was 10-fold slower. The peptide cleavage sites also varied between
tissue-cultured and primary cells, with 5- and 8-residue fragments formed in tumor cell lines and only the 8-residue fragment
formed in primary cells. These results demonstrate the ability of chemical cytometry to identify important differences in
enzymatic behavior between primary cells and tissue-cultured cell lines.
Pancreatic ductal adenocarcinoma (PDA) accounts forgreater than 90% of all types of pancreatic cancer and is
the fourth most common cause of cancer-related deaths in the
United States.1−4 PDA generally develops in adults over 50
years old adjacent to the pancreatic duct, often leading to
blockage of the pancreatic or bile ducts. PDA tumors frequently
invade deep into the pancreas and nearby organs and rapidly
metastasize to the lymph nodes prior to diagnosis.5,6 The
American Cancer Society estimates that there will be
approximately 45,220 new cases of PDA and 38,460 deaths
from PDA in the United States in 2013.5 Median survival for
patients diagnosed early (Stage I) is approximately 2 years, but
greater than 50% of individuals are not diagnosed until the late
stages, when the median survival decreases to 4.5 months.5
Treatment for patients with PDA includes surgical removal of
the cancer (approximately 20% of patients) as well as radiation
and chemotherapy, though these measures usually only relieve
symptoms and may briefly extend survival. Only rarely does
treatment yield a cure.5
Genetic alterations, including mutations, deletions, and
amplifications, of up to 12 different signaling pathways and
processes have been found in most pancreatic cancers,
including PDA.7 Among the pathways affected are those that
control apoptosis, DNA damage control, and tumor invasion,
all of which enable PDA tumors to survive and proliferate even
in the presence of anticancer therapies.8,9 Prominent among
these altered pathways is the PI3-K (phosphoinositide 3-
kinase) pathway, which regulates multiple cellular functions,
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including transcription, proliferation, stress response, and
apoptosis.10,11 Protein kinase B (PKB, also known as Akt) is
a serine/threonine kinase in the PI3-K pathway whose activity
has been implicated in providing cancer cells with antiapoptotic
properties, even in the presence of multiple apoptotic stimuli.8
This is particularly true in PDA, where the PI3-K/PKB pathway
has been found to be constitutively active and appears to be an
indicator of aggressiveness of the pancreatic cancer, with high
levels of active PKB associated with decreased patient
survival.12−16 While 10% of analyzed pancreatic carcinomas
show an amplification of AKT2 (one of 3 PKB genes), no other
genetic alterations have been reported for PKB or PI3-K in
pancreatic tumors, suggesting that alterations to the pathway
are occurring by misregulation of mRNA, protein levels, or
input from other pathways.2,17 Thus, PKB gene copy number
and protein levels often do not predict the level of PKB activity
in a tumor. Consequently, a strategy to directly measure PKB
activity in PDA tumors would be of high utility in under-
standing PKB signaling in PDA.
Currently, the most commonly utilized measurement of PKB
in resected PDA tumors is Western blot analysis, in which the
amount of active PKB is determined using antibodies directed
against phosphorylated PKB.2 However, this method reports
the population-averaged level of PKB activity and yields no
insight into tumor heterogeneity at the cellular level. It has long
been known that tumors are highly heterogeneous, with
differences arising from genetic, protein, and metabolic
diversity.18−20 By nature, bulk measurements cannot reveal
these differences, whereas interrogation of single cells has the
power to yield a wealth of information on single-cell dynamics.
Immunohistochemistry (IHC) measurement of phosphorylated
PKB has been used to assess PKB activity at the single-cell
level.2,12,14,15 Although IHC is valuable for determining
subcellular localization of active PKB in PDA tumor cells, it
is not quantitative. In contrast, chemical cytometry,21 which
utilizes sensitive analytical techniques to gather quantitative
data from individual cells, provides a direct single-cell
quantitative measurement of PKB activity.22 The application
of chemical cytometry for the analysis of PKB activity from
individual PDA tumor cells should furnish a comprehensive
assessment of PKB signaling heterogeneity within a tumor
biopsy.
Patient-derived xenograft (PDX) tumors have enabled novel
insights into human tumor cell biology as well as measurement
of tumor-cell response to pharmacologic therapies. PDX
tumors are formed by subcutaneously implanting a small
fragment of primary tumor into an immunocompromised
mouse.23 PDX cells can then be passaged over time to form a
renewable tissue resource. PDX models recapitulate the human
tumor microenvironment and maintain both the gene-
expression and genomic profiles as well as the morphology of
the original human tumor.23−27 Detailed IHC and allelotype
analysis of PDA-derived xenografts have demonstrated that the
degree of differentiation and nuclear polymorphisms in the
original tumor sample are maintained immediately after
establishment and following serial passage from one nude
mouse to another.28 PDX models are one of the most
promising models to deliver personalized therapeutics for
pancreatic cancer patients by permitting initial drug prescreen-
ing within the murine host.25 Furthermore, PDX models
provide an abundant and renewable source of primary PDA
cells which can be utilized to identify the aberrant signaling
pathways within single tumor cells.
In this work, capillary electrophoresis with laser-induced
fluorescence detection (CE-LIF) has been employed to
quantify PKB activity in single cells from tissue-cultured
models of PDA as well as from PDX tumors. A PKB substrate
was introduced into single cells, and the formation of
phosphorylated product was quantified at varying times and
substrate concentrations. For both model systems, the time-
averaged rates of peptide phosphorylation and proteolysis
within the single cells were measured at varying times and
peptide concentrations. The impact of the inhibitor wortman-
nin, an irreversible inhibitor of PI3-K, was assessed on peptide
phosphorylation and degradation to understand drug effects on
both metabolic processes. Comparisons between single cells
and among the primary PDX tumor cells and cultured cell lines
revealed important differences in the cell-to-cell variability
within cells from the same population as well as between cell
types.
■ EXPERIMENTAL SECTION
Materials, Peptide Synthesis, and Statistical Analysis.
Detailed information on materials, synthesis of peptides, and
the statistical analyses utilized can be found in the Supporting
Information.
Immortalized Cell Culture. PANC-1 (human pancreatic
carcinoma), CFPAC-1 (human metastatic ductal pancreatic
adenocarcinoma), HPAF-II (human pancreatic adenocarcino-
ma), and WI-38 (human lung tissue) cells were obtained from
the American Type Culture Collection.29−32 PANC-1 cells
were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), penicillin
(100 units mL−1), and streptomycin (100 μg mL−1). CFPAC-1
cells were grown in IMDM supplemented with 10% FBS,
penicillin (100 units mL−1), and streptomycin (100 μg mL−1).
HPAF-II and WI-38 cells were propagated in MEM
supplemented with 10% FBS, penicillin (100 units mL−1),
and streptomycin (100 μg mL−1). All cells were maintained in a
humidified atmosphere of 37 °C in 5% CO2 and passaged into
fresh media every 2−3 days. Cells used for single-cell CE
experiments were plated the day before the experiments onto
custom chambers, prepared by using poly(dimethylsiloxane)
(PDMS, Sylguard 184) to glue a silicon O-ring (McMaster-
Carr) to a #1 glass coverslip (Fisher). A dilute cell suspension
was added to 500 μL of the appropriate media in the chamber,
and chambers were placed in the humidified incubator until use
in the experiments.
Cell Preparation from Patient-Derived Xenografts.
Pancreatic tumor tissue from deidentified patients were
engrafted subcutaneously into the flanks of NSG/NOD
(nonobese diabetic scid gamma/nonobese diabetic) mice,
expanded, and passed over time. All animal experiments were
carried out ethically under protocols approved by the
University of North Carolina Institutional Animal Care and
Use Committee.27,33 Harvested tumors were immersed in
phosphate buffered saline (PBS; 137 mM NaCl, 27 mM KCl,
10 mM Na2HPO4, 1.75 mM KH2PO4, pH 7.4) with penicillin
(500 units mL−1) and streptomycin (500 μg mL−1) and
dissected into small fragments. Tumors were disaggregated by
incubating at 37 °C for 20−40 min in 40 mg mL−1 collagenase
D and Dispase II. After incubation, the mixture was centrifuged
at 1500g for 2 min prior to suspension in fresh media. The cell
suspensions were immediately plated onto cell chambers and
cultured in DMEM supplemented with 10% FBS, penicillin
(100 units mL−1), and streptomycin (100 μg mL−1) and
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maintained in a humidified atmosphere at 37 °C in 5% CO2.
The chambers used for single-cell experiments were made of a
thin film of polystyrene (146 ± 10 μm thick) prepared with
10% polystyrene in GBL and baked at 90 °C for 4 h and 120 °C
for 20 h, as described previously.34 PDMS was used to glue a
silicon O-ring (McMaster-Carr) to the polystyrene thin film to
create the chamber. Chambers were oxygen-plasma treated for
5 min and used either uncoated or coated with 0.1% gelatin. To
enable surface attachment, cells were plated in the chambers 36
h prior to use.
Western Blot. PANC-1, CFPAC-1, and HPAF-II cell
lysates were prepared on ice with RIPA buffer with protease
and phosphatase inhibitors. Cells treated with wortmannin
were incubated in 1 μM wortmanin for 10 min prior to lysis.
Protein extracts were quantified for total protein with a
Bradford Assay. The lysates were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) prior
to transfer to a PVDF membrane. Primary antibodies were
antiphospho-PKB (Ser473) rabbit antibody; anti-PKB rabbit
antibody directed against total PKB; and antivinculin mouse
antibody directed against vinculin. Secondary antibodies were
antirabbit or antimouse IgG conjugated to horseradish
peroxidase (HRP). Samples were visualized using an electro-
chemiluniescent substrate for HRP.
Single-Cell CE. Chambers with cells were placed on the
microscope stage and perfused with extracellular buffer [ECB;
135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 10
mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(HEPES), pH 7.4, 37 °C] to remove culture media. To
calculate cell volume, PDX tumor cells were modeled as
spheres and tissue-cultured cells were modeled as rectangles
with a height of 3 μm. Cell volume ranged from 1 to 15 pL,
with 62% of the cells between 3 and 8 pL. Peptide VI-B was
introduced into single cells by microinjection using finely
pulled glass capillaries (FemtoJet Injectman NI 2, Eppendorf,
Hauppauge, NY) and an injection pressure of 200 hPa for 0.5 s.
A single cell was microinjected with peptide VI-B and incubated
in ECB (37 °C) flowing at 3 mL min−1.
Single-cell CE was performed using a custom-built CE
system mounted on a microscope stage coupled to laser-
induced fluorescence detection as described previously.35,36 A
detailed description of the custom-built system can be found in
the Supporting Information. Fused silica capillaries [30 μm
inner diameter, 360 μm outer diameter (Polymicro Tech-
nologies, Phoenix, AZ)] had a total length of 38 cm and an
effective length of 21.5 cm. The electrophoretic buffer was 300
mM borate, pH 7.5, and a field strength of 260 V was applied
for separations. Electrophoresis was initiated by application of a
negative voltage to the outlet while the inlet was held at ground.
For single cells, the capillary was positioned approximately 20
μm above the cell of interest prior to cell lysis. A focused pulse
(5 ns) from an Nd:YAG laser created a cavitation bubble which
mechanically lysed the cell. Simultaneously, −3 kV was applied
to the capillary inlet while the outlet was held at ground so that
the cell’s contents were electrokinetically loaded into the
capillary inlet. The capillary inlet was then transferred to an
electrophoretic buffer reservoir and electrophoresis initiated.
To treat cells with the inhibitor wortmannin, media was
removed from the cell chamber and replaced with 500 μL of
500 nM wortmannin in the appropriate cell media. The cells
were incubated for 10 min in a 37 °C humidified incubator.
Cells were then treated as described above. To estimate the
amount of peptide in each cell, a known concentration of each
peptide was hydrodynamically loaded into the capillary and
electrophoresed, and the area under the resulting peak was
calculated. Poiseuille’s equation was utilized to estimate the
amount of peptide loaded into the capillary.37 Initial substrate
concentration in each cell was determined by dividing the
calculated number of moles microinjected into each cell by the
estimated cell volume.
Figure 1. Representative electropherograms from single-cell analysis of PANC-1 tissue-cultured cells without (A) and with (B) treatment with
wortmannin (WM). Peptide was incubated in cells for 5 min prior to analysis (A−C). The solid arrow indicates intact parent peptide, and the
asterisk indicates phosphorylated peptide. Peaks labeled 1 and 2 correspond to the 8- and 5-residue fragment peptides, respectively. Single-cell CE
(C) and Western blot (D) results of PKB activity assessment in tissue-cultured cells. The bars represent the median (C). Vinculin was used as a
loading standard (D).
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Antibody Staining. All PDX tumor samples were stained
with antihuman EpCAM antibody conjugated to AlexaFluor647
prior to single cell analysis. EpCAM-positive PANC-1 cells and
EpCAM-negative WI-38 cells were used as controls for
antibody staining. Cells in chambers were rinsed with ECB
and incubated in a 1:40 solution of anti-EpCAM in ECB for 15
min in a humidified 37 °C incubator. Cells were rinsed with
ECB prior to imaging (excitation = 620 ± 20 nm, emission =
690 ± 30 nm) using a CoolSnap HQ2 CCD camera
(Photometrics, Tucson, AZ). Only cells staining positive for
EpCAM were microinjected with peptide and analyzed by CE.
■ RESULTS AND DISCUSSION
Characterization of Peptidase Activity in Single
Tissue-Cultured Cells Derived from Pancreatic Adeno-
carcinomas. Three representative pancreatic cancer cell lines
were selected on the basis of their variability in PKB activity.
PANC-1 cells were derived from a 56-year old Caucasian male
with pancreatic cancer;31 CFPAC-1 cells were derived from the
liver of a 26-year old Caucasian male with cystic fibrosis and
pancreatic cancer;30 and HPAF-II cells were obtained from a
human pancreatic carcinoma isolated from the ascitic fluid of a
44-year old Caucasian male with primary pancreatic adeno-
carcinoma and metastases to the liver, diaphragm, and lymph
nodes.29 To assess the degradation of peptide-based reporters
in these tumor lines, a previously validated, peptidase-resistant
PKB substrate (peptide VI-B, 6FAM-GRP-MeArg-AFTF-
MeAla-NH2)
22 was microinjected into single cells. After a 5
min incubation, the cell was lysed and the cellular contents
separated by capillary electrophoresis. Peaks were identified as
intact peptide, phosphorylated peptide, and fragment peptide
based on comigration with standards. When peptide VI-B was
incubated in PANC-1 (n = 11), CFPAC-1 (n = 11), or HPAF-
II (n = 10) cells for 5 min, four peaks were present on the
electropherograms, corresponding to intact peptide, phos-
phorylated peptide, and two fragment peptides (Figures 1A
and S1, Supporting Information). The fragment peptides were
identified as the 5- and 8-residue fragments of the parent
peptide. The intact parent peptide accounted for 23 ± 10%, 39
± 13%, and 45 ± 2% of total peptide in PANC-1, CFPAC-1,
and HPAF-II cells, respectively. The abundances of the two
fragment peptides were similar among the three cell lines, with
PANC-1, CFPAC-1, and HPAF-II cells possessing 12 ± 3%, 9
± 5%, and 10 ± 2% of the 5-residue fragment and 38 ± 10%,
36 ± 17%, and 41 ± 4% of the 8-residue fragment, respectively,
after 5 min. These values are similar to those previously
measured in the prostate cancer cell line LNCaP (n = 19),
where the intact peptide was found to comprise 15 ± 5% of all
peptide present after 5 min and the 5- and 8-residue fragments
accounted for 13 ± 7% and 40 ± 13% of all peptide,
respectively.22
A time-averaged rate of degradation of intact VI-B in each
cell line was calculated by assuming 100 pg of total protein in
each cell.38 The time-averaged rate of degradation in PANC-1,
CFPAC-1, and HPAF-II cells was determined to have a median
of 0.02 zmol pg−1 s−1 (Q1 and Q3 of 0.007 and 0.06 zmol pg
−1
s−1); 0.06 zmol pg−1 s−1 (Q1 and Q3 of 0.03 and 0.09 zmol pg
−1
s−1); and 0.1 zmol pg−1 s−1 (Q1 and Q3 of 0.04 and 0.5 zmol
pg−1 s−1), respectively. The difference in amount of peptide
breakdown between cell lines was not statistically significant,
with p-values of 0.1710 (PANC-1 vs CFPAC-1), 0.5735
(PANC-1 vs HPAF-II), and 0.9008 (CFPAC-1 vs HPAF-II).
In each cell line, a plot of the time-averaged rate of degradation
of intact VI-B as a function of initial substrate concentration
revealed a direct linear correspondence between rate and
substrate concentration (Figure S2, Supporting Information).
These time-averaged rates of degradation did not statistically
differ (p-values all greater than 0.07) from that previously
reported for the degradation of peptide VI-B in LNCaP lysates,
with a median rate of 0.02 zmol pg−1 s−1 (Q1 and Q3 of 0.007
zmol pg−1 s−1 and 0.05 zmol pg−1 s−1).22 The first-order
relationship between degradation rate and substrate concen-
tration suggested that the capacity of the endogenous
peptidases was not saturated, even though substrate concen-
tration in individual cells varied over 3 orders of magnitude.
Similar observations have been previously reported.39−41 This
capacity for peptide metabolism may be the result of the need
to rapidly recycle large quantities of damaged proteins
produced in these rapidly growing tumor cells.
Measurement of PKB Activation in Single Tissue-
Cultured Cells Derived from Pancreatic Adenocarcino-
mas. In addition to the two fragment peaks observed in single
cells, phosphorylation of peptide VI-B was likewise seen in all
three cell types. After peptide VI-B was incubated in PANC-1
cells for 5 min (Figure 1C), the median amount of
phosphorylation was 65% (Q1 = 48% and Q3 = 71%).
Assuming a total protein content of 100 pg per cell, the
median time-averaged rate of phosphorylation was 0.01 zmol
pg−1 s−1 (Q1 and Q3 of 0.007 and 0.06 zmol pg
−1 s−1).
When peptide VI-B was incubated for 5 min in CFPAC-1
cells (Figure 1C), the median amount of phosphorylation was
21% (Q1 = 15% and Q3 = 45%). The distribution of
phosphorylated product appeared to be bimodal, with a cluster
of 6 cells showing smaller amounts of phosphorylation (8−
20%) and a cluster of 5 cells displaying larger amounts of
phosphorylation (41−60%). Statistical analysis of a much larger
population of cells will be required to evaluate whether or not
the behavior of the CFPAC-1 cells is truly bimodal. Percent
phosphorylation as a function of initial substrate concentration
was plotted to determine if a bimodal variation of the amount
of peptide injected into the cells would explain the varying
distribution of phosphorylation. However, there appeared to be
no correlation between initial substrate concentration and
percent phosphorylation (data not shown). Assuming 100 pg of
protein/cell, the median time-averaged rate of phosphorylation
in single CFPAC-1 cells was 0.01 zmol pg−1 s−1 (Q1 and Q3 of
0.009 and 0.03 zmol pg−1 s−1). The time-averaged rates
between the two groups of cells likewise differed, with a median
for the lower group of 0.01 zmol pg−1 s−1 (Q1 and Q3 of 0.008
and 0.08 zmol pg−1 s−1) and a median for the higher group of
0.04 (Q1 and Q3 of 0.01 and 0.06 zmol pg
−1 s−1). Work by
Cantley and others suggests that bimodal activation of the PKB
signaling pathway may occur in some cell types and confer
resistance to chemotherapy.42−45
In HPAF-II cells, the median amount of phosphorylation of
VI-B after a 5 min incubation was 4% (Q1 = 2% and Q3 = 7%;
Figure 1C) and the median time-averaged rate of phosphor-
ylation was 0.005 zmol pg−1 s−1 (Q1 and Q3 of 0.002 and 0.01
zmol pg−1 s−1). Single-cell analysis of substrate phosphorylation
in intact, single PANC-1, CFPAC-1, and HPAF-II cells revealed
a difference in the time-averaged rate of PKB activity among the
three lines, indicating high, moderate, and low amounts of
active PKB in the cells, respectively. A nonparametric Kruskal−
Wallis statistical analysis of variance of these three populations
demonstrated a statistically significant difference between the
three populations (p-value of 4.4 × 10−4). Previous work in the
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prostate cancer cell line LNCaP revealed a median phosphor-
ylation percentage of 31% (Q1 and Q3 of 12% and 44%) and a
median time-averaged phosphorylation rate of 0.01 zmol pg−1
s−1 (Q1 and Q3 of 0.004 and 0.03 zmol pg
−1 s−1), similar to the
median of the CFPAC-1 cells.22
Inhibition of PKB Activity in Tissue-Cultured Cells.
Wortmannin is an irreversible inhibitor of PI3-K at nanomolar
levels, blocking the phosphorylation of phoshatidylinositol
(4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3).
46 PIP3 recruits PKB to the plasma
membrane which leads to PKB phosphorylation and activation.
To determine whether phosphorylation of peptide VI-B was
sensitive to wortmannin, PANC-1 (n = 11), CFPAC-1 (n =
11), and HPAF-II (n = 10) cells were incubated with 500 nM
wortmannin prior to microinjection of peptide VI-B into single
cells and subsequent electrophoresis. In all three cell lines,
incubation with wortmannin eliminated the phosphorylation of
the peptide in single cells (Figure 1C). In all cases, there was a
statistical difference in the amount of VI-B phosphorylated in
treated and untreated cells (p-value <1 × 10−4 for all three cell
types). Inhibition of VI-B phosphorylation at these low
wortmannin concentrations suggests that the peptide was
predominantly acting as a substrate for PKB, as the wortmannin
concentration used was an order of magnitude less than that
reported for efficient inhibition of MLCK, the next kinase most
susceptible to wortmannin.46 Degradation of peptide VI-B was
observed in all wortmannin-treated cells, and both the 8- and 5-
residue fragments were observed in the majority of the
wortmannin-treated cells (Figures 1B and S2, Supporting
Information). A plot of the time-averaged rate of degradation of
parent peptide VI-B as a function of initial substrate
concentration (Figure S2, Supporting Information) revealed a
linear correlation with a positive slope. Furthermore, there was
no statistical difference between the time-averaged rate of
peptide degradation in wortmannin-treated and untreated cells
(p-values of 0.7705, 0.8810, and 0.9999 for PANC-1, CFPAC-1,
and HPAF-II cells, respectively.)
Active PKB Determined by Western Blot Analysis in
Cell Lysates Derived from Pancreatic Adenocarcinomas.
Western blot analysis was performed to compare single cell
results with the traditional bulk lysate measurements of PKB
activity for the three cell types (Figure 1D). Total PKB was
determined using an anti-PKB antibody sensitive to endoge-
nous levels of PKB1, PKB2, and PKB3. Active PKB was
determined using a monoclonal antibody against the
phosphorylated serine at position 473. The same trend was
observed as was seen in single cells, with PANC-1 cells showing
the highest amount of phosphorylated PKB, CFPAC-1 cells a
moderate amount, and HPAF-II cells the smallest amount.
Although the averaged data from the single cell measurements
matches that of the Western blots, single cell analysis revealed
the cell-to-cell heterogeneity not available via the more
traditional Western blot.
Wortmannin also decreased the amount of phosphorylated
Ser473 in the cell lysates, as determined by Western blot
(Figure 1D). The amount of pSer473 decreased in all three cell
lines when wortmannin was present, though the total amount
of PKB remained the same in treated and untreated samples.
Phosphorylation of Peptide VI-B over Time. To
determine the effect of incubation time on peptide phosphor-
ylation, peptide VI-B was microinjected into single tissue-
cultured cells and incubated for 1, 3, 5, 10, or 30 min (Figure
S3A−C, Supporting Information). In all cases, at least 10 cells
were analyzed for each time point. For all three cell types, only
a single HPAF-II cell showed phosphorylated product after a 1
min incubation. After a 3 min incubation, the CFPAC-1 cells
displayed the highest percentage of phosphorylated product
when compared to PANC-1 and HPAF-II cells. PANC-1 had
the highest median amount of phosphorylation after a 5 min
incubation, as described in the section Measurement of PKB
Activation in Single Tissue-Cultured Cells Derived from
Pancreatic Adenocarcinomas. This result held true at the 10
and 30 min time points as well. Table S1 (Supporting
Information) summarizes the median data with the first and
third quartiles for all 3 cells types at all incubation times. There
is heterogeneity in the amount of phosphorylated product at
nearly all time points sampled in all three cell types, although
the median amount of phosphorylated product peaked at 5 min
and decreased over time in the PANC-1 and CFPAC-1 cells
and appeared to level off after 5 min in the HPAF-II cells.
The time-averaged rate of phosphorylation as a function of
the initial substrate concentration for each cell type was plotted
in order to identify whether the initial amount of substrate
peptide loaded into each cell influenced the time-averaged
phosphorylation rate (Figure S3D−F, Supporting Information).
In all cell types at all 5 time points, a linear correlation was
Figure 2. Brightfield (A−C) and fluorescence (D−F) images of cells cultured on polystyrene coverslips and stained with the AlexaFluor647 anti-
EpCAM antibody. Shown are PANC-1 cells (A,D); WI-38 cells (B,E); and PDX tumor cells (C,F).
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observed, showing that as the initial substrate concentration
increased so did the time-averaged rate. This correlation was
independent of incubation time, as the same trend was
observed for all time points in all three cell types.
Measurement of PKB Activation in Single Cells
Derived from PDX Tumors. PDX tumor cells were readily
distinguished from nontumor cells by the presence of epithelial
cell adhesion molecule (EpCAM, also known as CD326) upon
immunohistochemical staining (Figure 2C,F). In these experi-
ments, PANC-1 cells (EpCAM+) and WI-38 fibroblast cells
(EpCAM−) served as positive and negative staining controls,
respectively, for these experiments (Figure 2A,B,D,E). PKB
activation was measured in single tumor cells by staining the
PDX tumor sample with anti-EpCAM antibody and then
microinjecting peptide VI-B into the EpCAM+ cells. Cells were
incubated at 37 °C for 5 or 10 min and their contents separated
by electrophoresis. Up to 3 peaks were observed in each single-
cell electropherogram: the intact parent peptide; phosphory-
lated substrate; and the 8-residue fragment peptide (Figure 3).
When incubated for 5 min, phosphorylation of peptide VI-B
ranged from 0% to 72% of the undegraded peptide (n = 11).
After a 10 min incubation, phosphorylation increased to 0−
89% of total intact peptide (n = 11). The range of peptide
phosphorylation, or PKB activation, in the PDX tumor cells was
substantially broader than that for the cultured cell lines
suggesting that the signaling pathways in PDX tumors were
more heterogeneous than cultured cell lines. These results are
consistent with the tumor heterogeneity observed during
single-cell sequencing,18 demonstrating the value of single-cell
characterization in understanding tumor cell biology.
Inhibition of PKB Activity in Single Cells Derived from
PDX Tumors. Cells were pretreated with wortmannin (500
Figure 3. Electropherograms of single EpCAM+ PDX tumor cells (A−C). Peptide VI-B was incubated in a single PDX tumor cell for 5 min without
(A) and with (B) pretreatment with wortmannin. Peptide VI-B was incubated in a single PDX tumor cell for 10 min without treatment with
wortmannin (C). The solid arrow indicates intact parent peptide, and the asterisk indicates phosphorylated peptide. Peak 1 corresponds to the 8-
residue fragment peptide. (D) Percent of phosphorylated substrate in single, EpCAM+ PDX tumor cells after different incubation times of peptide
VI-B in the cells. WM stands for wortmannin.
Figure 4. Degradation differences between tissue-cultured and PDX tumor cells. (A) Cleavage locations identified for each cell type tested. The
prostate cancer line LNCaP* data is from Proctor et al.22 The slope is defined as the change in the average degradation rate with respect to the initial
substrate concentration. R2 is the correlation coefficient for the fit of the straight line. (B) Degradation rate of peptide VI-B incubated in single
pancreatic cancer tissue-cultured cells (open circles) or PDX tumor cells (closed squares) as a function of initial substrate concentration. The dashed
line is the linear fit (R2 = 0.3) of the tissue-cultured data, and the solid line is the linear fit (R2 = 0.1) of the PDX tumor cell data.
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nM), stained with EpCAM, and then microinjected with
peptide VI-B. After a 5 min incubation, 5 of 6 cells displayed
two peaks on the electropherograms, which corresponded to
intact parent peptide and the 8-residue fragment (Figure 3B,D).
Phosphorylated peptide (1% of total intact peptide) was
present in only a single cell. These data suggest that PKB was
primarily responsible for phosphorylation of the substrate.
When the mean phosphorylation observed in wortmannin-
treated cells was compared to that seen in untreated cells at
both the 5 and 10 min time points, a statistical difference in
phosphorylation was observed (p-values of 0.0015 and 1 ×
10−4, respectively).
Degradation of Peptide VI-B in Single Cells Derived
from PDX Tumors. In addition to the intact parent peptide
and its phosphorylated counterpart, the 8-residue fragment
peptide was also detected in the PDX tumor cells (Figures 3
and 4). However, it was present in much lower amounts than in
the tissue-cultured lines previously tested, with a median of
11% of all peptide present (Q1 and Q3 of 7% and 12%). When
compared against the standard tissue-cultured cells, this value
was found to be significantly lower than in any of the three cell
types analyzed (p-value of <10−4 in all three cases.) The 5-
residue fragment was not observed in any of the PDX tumor
cells examined (n = 28), though it was prevalent in tissue-
cultured cells. Figure 4A details the degradation pattern
between tissue-cultured and PDX tumor cells.
For the PDX tumor cells, the average rate of peptide
degradation depended on the initial substrate concentration
(Figure 4B). When fit to a line, the slope was 0.26 zmol μM−1
s−1, an order of magnitude less than that seen for the tissue-
cultured cells in this work and in prior work using other tissue-
cultured cells,22 suggesting that the peptidases responsible for
degradation of peptide VI-B are substantially less active in the
PDX tumor cells compared to that in tissue-cultured cells.
Analysis of covariance of the two regression lines generated an
F-statistical value of 7.598 (yielding a p-value <10−4) indicating
that there was a statistical difference in the two regression lines.
■ CONCLUSIONS
A PKB substrate peptide was utilized as a dual reporter to
simultaneously measure peptidase and kinase activity in single,
intact pancreatic cancer cells. The reporter was degraded into
two fragment peptides (a 5-mer and an 8-mer) in all three
tissue-cultured cell types analyzed, similar to that observed in
previous studies using prostate cancer cells.22 Reporter
degradation in single PDX tumor cells differed from that of
the tissue-cultured cells in both the location of cleavage and the
time-averaged rate of degradation. Although two cleavage sites
were identified in tissue-cultured cells, only one (the 8-mer)
was observed in the PDX tumor cells. A search of the peptidase
database MEROPS47 reveals that, of the common cytosolic
peptidases, dipeptidyl peptidase II preferentially cleaves after an
alanine residue, which would yield the 5-mer observed in these
studies. Thus, it is possible that the tissue-cultured cells
overexpress this particular cytosolic peptidase compared to the
primary cells. This may be an adaptation of the tissue-cultured
cell-lines to prolonged culture in an in vitro setting. In addition,
the time-averaged rate of degradation in PDX tumor cells was
an order of magnitude less than that seen in tissue-cultured
cells, demonstrating that peptidases are less active or more
tightly controlled in the PDX cells than the tissue-cultured lines
which is likely a second adaptation to prolonged in vitro culture.
PKB activity was also assessed in single cells by comparing
the amount of phosphorylated product to the amount of
substrate loaded into each cell. High PKB activity in pancreatic
cancer tumors is associated with resistance to apoptosis, higher
rates of metastasis and mutations, and increased proliferation
and uninhibited growth.48 The PANC-1 tissue-cultured cells
displayed the highest median amount of PKB activity of the
three cell lines examined, implying that they are more adapted
for survival in stressful environments and are likely to show
increased rates of proliferation and resistance to stress
compared to other cell types. Although a much larger
population of CFPAC-1 cells would need to be analyzed to
identify whether or not the PKB signaling is truly bimodal, our
results suggest this might be a possibility. If high and low states
of PKB activity do exist within this population, it would provide
these cells with a means to survive chemotherapeutic insults,
with the population shifting to one extreme or the other in
response to drug treatment.
The PKB activity measured in the PDX cells varied more
than that seen in the tissue-cultured cells, with many cells
showing no PKB activity and others demonstrating very high
levels of substrate phosphorylation. This suggests that the
individual cells in the animal might be adapted to the different
environmental conditions within the tumor whereas the tissue-
cultured cells are expected to experience significantly less
environmental variability. For example, a low pH and anoxic
tumor region might require greater PKB activity to survive the
resulting stresses compared to a well-vascularized, lower-stress
region of a tumor. The tumor heterogeneity would ensure
tumor survival under the varying conditions found in vivo.
As this technology matures to become higher throughput,
single-cell CE may be of value in monitoring PKB activity levels
in single cells from patients diagnosed with PDA. Previous
studies have shown that inhibition of the PI3-K/PKB pathway
sensitizes pancreatic cancer cells to chemotherapy.48,49 Thus, a
better understanding of whether the PI3-K/PKB pathway is
active in a patient’s tumor as well as knowledge of the diversity
in single-cell signaling would be a valuable guide to tailoring
chemotherapeutics. Single-cell CE can be used to determine the
effectiveness PI3-K/PKB pathway inhibition within a cell
population and whether a subset of cells has become resistant
to PI3-K/PKB pathway-targeted therapeutics. Tracking the
evolution of PI3-K/PKB pathway signaling in a tumor in
response to therapy may enable more tailored therapeutic
strategies than currently available.
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